Phone Number
(800) 210-7017
(800) 210-7017
Here’s the part of PRP that almost nobody reads carefully until a warning letter arrives: the FDA clearance on your kit isn’t a green light for the conditions you’re treating. It’s a narrow permission to mix platelets with bone graft material, and the gap between that letter and your actual practice is where your regulatory exposure lives. Knowing exactly what your kit’s indications-for-use page says, before you buy it, is the single biggest-payoff move you can make as a clinician or owner.
The overwhelming majority of PRP kits on the U.S. market are 510(k)-cleared as Class II automated blood cell separators with a single narrow orthopedic bone-graft mixing indication, and every off-label use, including tendon, joint, hair, and aesthetic applications, sits outside what the FDA clearance letter actually authorizes.
The FDA treats your centrifuge as a moderate-risk blood-handling device, not as a biologic and not as a high-risk implant. That sounds technical, but it sets the entire ceiling on what the clearance can claim and how much evidence the manufacturer ever had to produce to get the kit on the market.
PRP kits clear the FDA as Class II devices through a 510(k) substantial-equivalence pathway that requires no clinical effectiveness data, only bench performance and equivalence to a previously cleared predicate.
The indication-for-use page is the document you should read before you read anything else about a kit. The language is remarkably consistent across vendors and it almost never says what the sales rep implies it says, which is why verifying the K-number in the FDA’s own database is non-negotiable.
Nearly every PRP kit on the U.S. market is cleared only for the safe and rapid preparation of autologous PRP to be mixed with autologous or allogeneic bone graft material for application to a bony defect, and any use for tendon, joint, skin, or hair is off-label regardless of what the marketing implies.
Off-label use is legal, common, and the foundation of almost every PRP injection practice in the country. What changes when you cross that line isn’t the legality of the procedure; it’s who carries the burden of justifying it. The manufacturer steps out and you, the clinician, step in.
Off-label PRP use is legal for the clinician but shifts the entire burden of medical justification, evidence citation, informed consent, and accurate patient-facing language from the manufacturer onto the prescribing physician.
The reason every PRP kit you encounter is cleared for the same narrow bone-graft indication isn’t a coincidence and it isn’t a conspiracy. It’s the predicate chain doing exactly what the 510(k) pathway was designed to do, which is to keep new devices close to old ones. Once that chain locked onto orthopedic bone grafting in the late 1990s, it became the path of least resistance for every subsequent submission.
The 510(k) predicate chain has made bone-graft mixing the only commercially viable PRP indication, because any broader claim would force a manufacturer off the substantial-equivalence pathway and into De Novo or PMA territory requiring full clinical trial evidence.
FDA’s definition of labeling is wider than most people realize. It isn’t just the printed insert in the box; it’s the website, the booth banner, the rep’s slide deck, the social post, and the training video. Anything the manufacturer puts into circulation about the product gets pulled into the labeling bucket, and that’s where most enforcement starts.
| Channel | Permitted | Prohibited |
|---|---|---|
| Website and brochures | Bone-graft mixing language matching the clearance letter | Tendinopathy, OA, hair, or aesthetic treatment claims |
| Sales rep training | Cleared indication, ISO data, technical specs | Off-label protocol guides, before-and-after photo decks |
| Reprint distribution | Unaltered independent peer-reviewed studies with disclosure | Curated reprint packets framed as marketing for off-label use |
| Conference materials | Cleared indication and bench performance data | Case-report videos or testimonials covering off-label uses |
A 510(k)-cleared PRP kit can be promoted only for the bone-graft indication on its clearance letter, and any first-party manufacturer communication that names osteoarthritis, tendinopathy, hair restoration, or aesthetic use is misbranding under section 502 of the Act.
Same-procedure autologous PRP gets a regulatory pass that most people never realize they’re relying on. The moment any one of a handful of variables changes, that pass disappears and you’re suddenly in 351 biologic territory needing a full BLA. Knowing which moves break the exception is the difference between a compliant point-of-care procedure and an unapproved drug.
Autologous point-of-care PRP sits outside the 21 CFR Part 1271 framework entirely under the same-surgical-procedure exception, but adding cell expansion, off-site processing, allogeneic sourcing, or combination with non-exempt articles like hyaluronic acid converts it into a regulated 351 biologic requiring a BLA.
You don’t have to lose sleep over enforcement, but you do have to respect that the risk is real, layered, and getting more active. The FDA isn’t the only agency watching; state medical boards and consumer protection offices have been the more aggressive enforcer for cash-pay PRP marketing, and the False Claims Act adds a third front anytime federal payers are in the mix.
PRP enforcement now comes from three parallel directions, the FDA warning letter system targeting manufacturer promotion, state medical boards and consumer protection offices targeting clinician advertising claims, and False Claims Act qui tam suits targeting federally reimbursed off-label billing.
“Cleared” and “approved” sound interchangeable in everyday speech and they are anything but. The difference is whether the FDA ever evaluated effectiveness for a defined clinical indication, and for every PRP kit on the U.S. market the answer is no. Getting this language right is one of the cheapest insurance policies you can buy against a warning letter or a state board complaint.
| Dimension | 510(k) Clearance | PMA Approval |
|---|---|---|
| Device class | Class II (moderate risk) | Class III (life-sustaining or high risk) |
| Evidentiary standard | Substantial equivalence to a predicate | Reasonable assurance of safety AND effectiveness |
| Clinical trial required | Generally no, bench data only | Yes, typically a pivotal randomized trial |
| Correct verb | “FDA-cleared” | “FDA-approved” |
| PRP kit status | All marketed kits sit here, bone-graft indication | No PRP kit has ever achieved this |
No PRP centrifuge kit on the U.S. market has been granted PMA or De Novo clearance for a clinical indication such as knee osteoarthritis, tendinopathy, or hair restoration, and the only accurate description is FDA-cleared to prepare the patient’s own platelets, with clinical evidence for any specific condition coming from independent peer-reviewed literature rather than an FDA effectiveness determination.
